The Cancer Letter

Inside information on cancer research and drug development

In Brief

WashU and Siteman receive $11.6M SPORE grant for endometrial cancer research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Washington University School of Medicine in St. Louis and Siteman Cancer Center received a $11.6 million grant through the NCI’s Specialized Programs of Research Excellence. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Jemperli + Zejula improved PFS in advanced or recurrent endometrial cancer in RUBY Part 2 phase III trial

In a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by dostarlimab plus Zejula (niraparib) as maintenance therapy, in adult patients with primary advanced or recurrent endometrial cancer, the trial met its primary endpoint of progression-free survival.
Clinical Roundup

DUO-E phase III trial: Imfinzi + Lynparza reduces risk of progression/death vs. chemo in advanced/recurrent endometrial cancer

Imfinzi (durvalumab) plus platinum-based chemotherapy, followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy alone in the overall trial population of patients with newly diagnosed advanced or recurrent endometrial cancer. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account